Moneycontrol PRO
HomeNewsBusinessCompaniesNatco Pharma did not follow quality control measures: USFDA

Natco Pharma did not follow quality control measures: USFDA

The US drug regulator has made six observations after the completion of inspection of its Kothur formulation facility in Telangana, Natco said today in a statement.

January 25, 2017 / 14:37 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    The US Food and Drug Administration (FDA) has noted that city-based Natco Pharma did not follow quality control measures "fully" at its formulation plant in Telangana.

    The US drug regulator has made six observations after the completion of inspection of its Kothur formulation facility in Telangana, Natco said today in a statement.

    "The responsibilities and procedures applicable to the quality control unit are not fully followed...The written stability testing programme is not followed," FDA said in its inspection report.

    The FDA had inspected the Kothur formulation facility between January 16-24, 2017, Natco Pharma said in a statement.

    The company, however, stated that all observations are "correctable and procedural and it believes are minor in nature".

    "The observations are related to complaint and incident investigations, stability backlog and procedural SOPs," it said.

    Natco Pharma said it will provide due justifications and corrective action plan within next 15 working days to the address the USFDA observations.

    "Laboratory control does not include the establishment of scientifically and sound and appropriate specification and test procedures designed to assure that components, labelling and drug products confirmed to appropriate standards of identity, strength, quality and purity," FDA report said.

    In August last year, the drug firm had received Establishment Inspection Report (EIR) for the same facility from the US health regulator after successful completion of inspection.

    EIR is given to an establishment after the completion of the inspection by the USFDA.

    "Procedures designed to prevent micro biological contamination of drug products purporting to be sterile or not established, written and follow," the Regulator observed in its report.

    Natco shares were trading at Rs 643.15 on BSE at 13.40 hrs.

    first published: Jan 25, 2017 02:36 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347